FDA Determines Regulatory Review Period for Anipryl Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for Anipryl, a prescription animal drug, following a submission to the US Department of Commerce for patent extension, as mandated by law.